<SEC-DOCUMENT>0001157523-13-005136.txt : 20131030
<SEC-HEADER>0001157523-13-005136.hdr.sgml : 20131030
<ACCEPTANCE-DATETIME>20131030173012
ACCESSION NUMBER:		0001157523-13-005136
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20131030
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20131030
DATE AS OF CHANGE:		20131030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MANNKIND CORP
		CENTRAL INDEX KEY:			0000899460
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133607736
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50865
		FILM NUMBER:		131180252

	BUSINESS ADDRESS:	
		STREET 1:		28903 NORTH AVE PAINE
		CITY:			VALENCIA
		STATE:			CA
		ZIP:			91355
		BUSINESS PHONE:		6617755300

	MAIL ADDRESS:	
		STREET 1:		28903 NORTH AVE PAINE
		CITY:			VALENCIA
		STATE:			CA
		ZIP:			91355
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a50739928.htm
<DESCRIPTION>MANNKIND CORPORATION 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2013 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <p>

    </p>
    <hr style="width: 100%; text-align: center; color: #000000; height: 1.0 pt">


    <p style="text-align: center">
      <br>
      <font style="font-size: 14pt; font-family: Times New Roman">UNITED STATES</font><font style="font-size: 14pt; font-family: Times New Roman"><br style="font-size: 14pt; font-family: Times New Roman"></font><font style="font-size: 14pt; font-family: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font><font style="font-size: 12pt"><br style="font-size: 12pt"></font><font style="font-size: 12pt; font-family: Times New Roman">WASHINGTON,
      D.C. 20549</font><br>
    </p>
    <hr style="width: 100%; text-align: left; color: #000000; height: 1.0 pt">


    <p style="text-align: center">
      <br>
      <font style="font-size: 12pt; font-family: Times New Roman">FORM 8-K</font><br>
    </p>
    <hr style="width: 100%; text-align: left; color: #000000; height: 1.0 pt">


    <p style="text-align: center">
      <br>
      <font style="font-size: 12pt; font-family: Times New Roman">CURRENT
      REPORT</font><br><font style="font-size: 12pt; font-family: Times New Roman">Pursuant
      to Section 13 or 15(d) of the</font><br><font style="font-size: 12pt; font-family: Times New Roman">Securities
      Exchange Act of 1934</font><br><br><font style="font-size: 10pt; font-family: Times New Roman">Date
      of Report (Date of earliest event reported): October 30, 2013</font><font style="font-size: 10pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 10pt"></font>
    </p>
    <hr style="width: 100%; text-align: left; color: #000000; height: 1.0 pt">


    <p style="text-align: center">
      <br>
      <font style="font-size: 12pt; font-family: Times New Roman">MannKind
      Corporation</font><br><font style="font-size: 10pt; font-family: Times New Roman">(Exact
      name of registrant as specified in its charter)</font><br>
    </p>
    <hr style="width: 100%; text-align: left; color: #000000; height: 1.0 pt">


    <p style="text-align: center">
      <br>

    </p>
<div style="text-align:left">
    <table style="width: 100%; margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt" cellspacing="0">
      <tr>
        <td style="width: 33%; text-align: center; padding-left: 0.0px" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">Delaware</font>
          </p>
        </td>
        <td style="width: 34%; white-space: nowrap; text-align: center; padding-left: 0.0px; padding-right: 0.0px" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            000-50865
          </p>
        </td>
        <td style="width: 33%; white-space: nowrap; text-align: center; padding-left: 0.0px; padding-right: 0.0px" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            13-3607736
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 33%; text-align: center; padding-left: 0.0px" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (State or other jurisdiction of
          </p>
          <p style="margin-top: 0px; margin-bottom: 0px">
            incorporation or organization)
          </p>
        </td>
        <td style="width: 34%; text-align: center; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (Commission<br>File Number)
          </p>
        </td>
        <td style="width: 33%; text-align: center; padding-left: 0.0px" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (IRS Employer
          </p>
          <p style="margin-top: 0px; margin-bottom: 0px">
            Identification No.)
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>
      <br>

    </p>
<div style="text-align:left">
    <table style="width: 100%; margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt" cellspacing="0">
      <tr>
        <td style="width: 50%; text-align: center; padding-left: 0.0px" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <font style="font-size: 10pt">28903 North Avenue Paine Valencia,
            California</font>
          </p>
        </td>
        <td style="width: 50%; white-space: nowrap; text-align: center; padding-left: 0.0px; padding-right: 0.0px" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <font style="font-size: 10pt">91355</font>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 50%; text-align: center; padding-left: 0.0px" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">(Address
            of principal executive offices)</font>
          </p>
        </td>
        <td style="width: 50%; text-align: center; padding-left: 0.0px" valign="bottom">
          <font style="font-size: 10pt; font-family: Times New Roman">(Zip
          Code)</font>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">
      <br>
      Registrant&#8217;s Telephone Number, Including Area Code: (661)&#160;775-5300<br><br>N/A<br>&#160;(Former
      name or former address, if changed since last report)<br><br>
    </p>
    <hr style="color: #000000; width: 100%; text-align: left; height: 1.0 pt">


    <p>
      <font style="font-size: 10pt; font-family: Times New Roman">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions </font>(<i>see</i> General Instruction A.2.
      below)<font style="font-size: 10pt; font-family: Times New Roman">:</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font>
    </p>
    <div style="text-indent: 0pt; margin-bottom: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
<div style="text-align:left">
    <table style="width: 100%; margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt" cellspacing="0">
      <tr>
        <td style="width: 10%; text-align: left; padding-left: 0.0px" valign="top">
          Item 8.01
        </td>
        <td style="width: 90%; text-align: left; padding-left: 0.0px" valign="top">
          Other Events.
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: justify">
      On October 30, 2013, we announced that the U.S. Food and Drug
      Administration (FDA) has acknowledged the resubmission of a New Drug
      Application (NDA) for AFREZZA<sup>&#174;</sup> (insulin human [rDNA
      origin]) Inhalation Powder. The FDA considered the updated NDA to be a
      complete class 2 response to its Complete Response Letter issued in
      January 2011 and assigned a user fee goal date of April 15, 2014.
    </p>
    <p style="text-align: justify">
      On October 30, 2013, we issued a press release announcing the FDA's
      acknowledgement of the resubmission of the NDA for AFREZZA, a copy of
      which is attached as Exhibit 99.1 to this current report.
    </p>
<div style="text-align:left">
    <table style="width: 100%; margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt" cellspacing="0">
      <tr>
        <td style="width: 10%; text-align: left; padding-left: 0.0px" valign="top">
          Item 9.01
        </td>
        <td style="width: 90%; text-align: left; padding-left: 0.0px" valign="top">
          Financial Statements and Exhibits.
        </td>
      </tr>
    </table>
    </div>
    <p style="text-indent: 30.0px; font-size: 10pt">
      (d)&#160;Exhibits. The following exhibits are filed herewith:
    </p>
<div style="text-align:left">
    <table style="width: 100%; margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt" cellspacing="0">
      <tr>
        <td style="width: 5%; text-align: left; padding-left: 0.0px" valign="middle">

        </td>
        <td style="width: 1%; text-align: left; padding-left: 0.0px" valign="bottom">
          &#160;
        </td>
        <td style="width: 94%; text-align: left; padding-left: 0.0px" valign="middle">

        </td>
      </tr>
      <tr>
        <td style="width: 5%; white-space: nowrap; text-align: left; padding-left: 0.0px; padding-right: 0.0px" valign="top">
          99.1
        </td>
        <td style="width: 1%; text-align: left; padding-left: 0.0px" valign="bottom">

        </td>
        <td style="width: 94%; text-align: left; padding-left: 0.0px" valign="top">
          Press Release of MannKind Corporation dated October 30, 2013,
          announcing FDA&#8217;s acknowledgement of MannKind&#8217;s resubmission of the
          NDA for AFREZZA.
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="text-indent: 0pt; margin-bottom: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman"><b>SIGNATURE</b></font>
    </p>
    <p style="text-align: left">
      <font style="font-size: 10pt; font-family: Times New Roman">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.</font>
    </p>
<div style="text-align:left">
    <table style="width: 50%; margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt" cellspacing="0">
      <tr>
        <td style="text-align: left; padding-left: 0.0px" valign="top" colspan="2">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 24%">

        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 70%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            MANNKIND&#160;CORPORATION
          </p>
        </td>
        <td style="width: 24%">

        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 70%">

        </td>
        <td style="width: 24%; text-align: left; padding-left: 0.0px" valign="top">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 6%; text-align: left; padding-left: 0.0px; padding-bottom: 2.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            By:
          </p>
        </td>
        <td style="width: 70%; text-align: left; padding-left: 0.0px; border-bottom: solid black 1.0pt" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            /s/ David Thomson, Ph.D., J.D.
          </p>
        </td>
        <td style="width: 24%">

        </td>
      </tr>
      <tr>
        <td style="width: 6%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 70%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Name:&#160;&#160;&#160;David Thomson, Ph.D., J.D.
          </p>
        </td>
        <td style="width: 24%">

        </td>
      </tr>
      <tr>
        <td style="width: 6%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 70%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Title:&#160;&#160;&#160;&#160;Corporate Vice President,
          </p>
        </td>
        <td style="width: 24%">

        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 70%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;General Counsel and Secretary
          </p>
        </td>
        <td style="width: 24%">

        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 70%">

        </td>
        <td style="width: 24%; text-align: left; padding-left: 0.0px" valign="top">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 6%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Dated:
          </p>
        </td>
        <td style="width: 70%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            October 30, 2013
          </p>
        </td>
        <td style="width: 24%">

        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: left">

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a50739928_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2013 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 8pt; font-family: Times New Roman">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>MannKind
      Announces FDA Acknowledgement of Resubmission of New Drug Application
      for AFREZZA</b></font>
    </p>
    <p>
      VALENCIA, Calif.--(BUSINESS WIRE)--October 30, 2013--<b>MannKind
      Corporation (Nasdaq: MNKD)</b> today announced that the U.S. Food and
      Drug Administration (FDA) has acknowledged the resubmission of a New
      Drug Application (NDA) for AFREZZA<sup>&#174;</sup> (insulin human [rDNA
      origin]) Inhalation Powder. The FDA considered the updated NDA to be a
      complete class 2 response to its Complete Response Letter issued in
      January 2011 and assigned a user fee goal date of April 15, 2014.
    </p>
    <p>
      <b>About MannKind Corporation</b>
    </p>
    <p>
      MannKind Corporation (Nasdaq: MNKD) focuses on the discovery,
      development and commercialization of therapeutic products for patients
      with diseases such as diabetes. Its lead product candidate, AFREZZA<sup><b>&#174;</b></sup>,
      has completed Phase 3 clinical trials. MannKind maintains a website at <u>www.mannkindcorp.com</u>
      to which MannKind regularly posts copies of its press releases as well
      as additional information about MannKind. Interested persons can
      subscribe on the MannKind website to e-mail alerts that are sent
      automatically when MannKind issues press releases, files its reports
      with the Securities and Exchange Commission or posts certain other
      information to the website.
    </p>
    <p>
      CONTACT:<br>Company Contact:<br>MannKind Corporation<br>Matthew Pfeffer<br>Chief
      Financial Officer<br>661 775-5300<br><u>mpfeffer@mannkindcorp.com</u><br>or<br>Media
      Inquiries:<br>MCS Healthcare Public Relations<br>Laura De Zutter or Jeff
      Hoyak<br>800 477-9626<br><u>jeffh@mcspr.com</u><br><u>laurad@mcspr.com</u>
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
